Marimed (MRMD) Liabilities and Shareholders Equity (2011 - 2026)

Marimed (MRMD) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $201.2 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $201.2 million, down 3.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $813.7 million (down 2.69% YoY), and the FY2025 annual result was $202.6 million, down 2.14% from the prior year.
• Liabilities and Shareholders Equity eased to $201.2 million in Q1 2026 per MRMD's latest filing, from $202.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $212.7 million in Q3 2024 and troughed at $135.9 million in Q2 2022.
• A 5-year average of $187.2 million and a median of $201.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 52.23% in 2022, then declined 3.33% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $152.2 million in 2022, then increased by 28.86% to $196.1 million in 2023, then gained by 5.54% to $207.0 million in 2024, then declined by 2.14% to $202.6 million in 2025, then retreated by 0.68% to $201.2 million in 2026.
• Business Quant data shows MRMD's Liabilities and Shareholders Equity at $201.2 million in Q1 2026, $202.6 million in Q4 2025, and $205.6 million in Q3 2025.